Sensus Healthcare Past Earnings Performance
Past criteria checks 0/6
Sensus Healthcare's earnings have been declining at an average annual rate of -31.4%, while the Medical Equipment industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 6.7% per year.
Key information
-31.38%
Earnings growth rate
-31.28%
EPS growth rate
| Medical Equipment Industry Growth | 8.90% |
| Revenue growth rate | 6.74% |
| Return on equity | -17.07% |
| Net Margin | -34.50% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jul 06
SRTS: 2026 Reimbursement Shift Will Drive Upside Despite Softer Assumptions
Analysts have reduced their price target on Sensus Healthcare by $1, citing slightly softer assumptions for fair value, revenue growth, profit margins, and a higher future P/E multiple in their updated models. What's in the News Sensus Healthcare reported that from January 1, 2026 to March 31, 2026, it repurchased 0 shares for US$0 million under its existing share buyback program.
Narrative Update • Jun 22
SRTS: Future Upside Will Hinge On 2026 Margin Recovery
Analysts have trimmed their price target on Sensus Healthcare by $1 to $5.75, citing updated assumptions on long term profit margin and a lower future P/E multiple. What’s in the News for Sensus Healthcare Sensus Healthcare reported that from January 1, 2026 to March 31, 2026, the company repurchased 0 shares under its existing buyback program.
Narrative Update • Jun 04
SRTS: 2026 Reimbursement Codes Will Support Long Term Earnings Potential
Analysts have reduced their price target on Sensus Healthcare by $1 to $6, reflecting a lower fair value estimate and sharply reduced profit margin assumptions, partly offset by expectations for continued revenue growth from the SRT platform, supported by new reimbursement codes planned for 2026. Analyst Commentary Recent research points to a more cautious tone around Sensus Healthcare, with the trimmed price target reflecting reduced profit margin assumptions, even as analysts still factor in potential revenue contribution from the SRT platform and future reimbursement changes planned for 2026.Narrative Update • May 19
SRTS: Future Returns Will Hinge On 2026 Reimbursement Code Reset
Analysts have trimmed their price target on Sensus Healthcare from $6.88 to $5.75, citing revised fair value assumptions that factor in updated expectations for revenue growth, profit margins and a much higher future P/E multiple linked to anticipated demand for the SRT platform and new 2026 reimbursement codes. Analyst Commentary Recent research highlights both optimism and caution around Sensus Healthcare as analysts recalibrate their expectations and fair value work.Narrative Update • Apr 25
SRTS: 2026 Reimbursement Codes And New Platform Rollout Will Drive Upside
Narrative Update Overview Analysts have trimmed their average price target on Sensus Healthcare from $8.00 to $7.50, reflecting mixed views that balance expectations for stronger SRT platform revenue supported by new 2026 reimbursement codes, alongside the impact of recent quarterly results that fell short due to no sales from a key customer. Analyst Commentary Bullish analysts remain constructive on Sensus Healthcare, pointing to the company’s SRT platform and upcoming reimbursement changes as key elements that could support long term growth.Narrative Update • Apr 10
SRTS: 2026 Reimbursement Shift Will Support Future Skin Therapy Adoption
Analysts have updated the price target range for Sensus Healthcare. One analyst raised the target to $7.50, citing expectations for SRT platform revenue supported by new 2026 reimbursement codes.Narrative Update • Mar 27
SRTS: Reimbursement Shift In 2026 Will Drive Future Upside Potential
Narrative Update: Sensus Healthcare (SRTS) The blended analyst price target for Sensus Healthcare has shifted from $8 to $7.50. Analysts are balancing expectations for very strong SRT platform revenue in 2026, tied to new reimbursement codes, with the impact of Q4 results that missed forecasts due to no sales from the company’s largest customer.Narrative Update • Mar 10
SRTS: Future Upside Will Depend On 2026 Reimbursement Code Changes
Analysts have nudged their fair value estimate for Sensus Healthcare slightly higher to $6.88, reflecting mixed recent research in which one firm trimmed its price target to $6 after weak Q4 results, while another initiated coverage with a more upbeat $7.50 target tied to expectations for the SRT platform and 2026 reimbursement changes. Analyst Commentary Bullish Takeaways Bullish analysts point to the SRT-100/Vision platform as the core driver of the current fair value view, given its focus on treating both oncological and non-oncological skin conditions, which supports their more constructive stance on long term growth potential.Narrative Update • Feb 24
SRTS: Future Upside Will Hinge On Reducing Largest Customer Concentration Risk
Narrative Update on Sensus Healthcare Analysts have trimmed their price target on Sensus Healthcare to $6 from $8, pointing to Q4 results that came in well below their expectations after the company reported no sales from its largest customer. Analyst Commentary Analysts are adjusting their views on Sensus Healthcare after the latest Q4 report, with the lower price target reflecting both execution concerns and how the market may now be valuing the shares.Analysis Article • Feb 15
Sensus Healthcare, Inc. (NASDAQ:SRTS) Just Reported And Analysts Have Been Cutting Their Estimates
As you might know, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) last week released its latest annual, and things did not...Narrative Update • Feb 10
SRTS: Auditor Transition And Margin Outlook Will Support Future Upside
Analysts have reduced their price target on Sensus Healthcare to US$20.65 from US$21.29, reflecting updated assumptions that include slightly higher projected revenue growth, a modestly stronger profit margin profile, and a marginally lower future P/E multiple. What's in the News Auditor change: Sensus Healthcare's Audit Committee dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP and approved Carr, Riggs & Ingram, LLC as the new independent registered public accounting firm following CRI's acquisition of certain BPB capital markets assets, effective January 1, 2026 (Key Developments).Narrative Update • Jan 25
SRTS: Slightly Improved Outlook And Auditor Transition Will Support Future Upside
Analysts have raised their price target on Sensus Healthcare by a small amount, citing slightly higher assumptions for revenue growth and profit margins, along with a modestly lower discount rate and a marginally reduced future P/E multiple. What's in the News The Audit Committee of Sensus Healthcare's Board of Directors dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent registered public accounting firm and approved Carr, Riggs & Ingram, LLC as the new auditor, following CRI's acquisition of certain capital markets assets from BPB effective January 1, 2026 (company filing).Analysis Article • Jan 14
Sensus Healthcare, Inc.'s (NASDAQ:SRTS) Share Price Boosted 38% But Its Business Prospects Need A Lift Too
Despite an already strong run, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares have been powering on, with a gain of 38...Narrative Update • Jan 10
SRTS: Keloid Treatment Breakthrough Will Support Stronger Prospects Despite Trimmed Outlook
Narrative Update on Sensus Healthcare Analysts have modestly raised their price target on Sensus Healthcare, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E. Together, these adjustments support a higher fair value estimate now framed at US$8.00.Narrative Update • Dec 26
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have modestly lifted their price target on Sensus Healthcare to reflect slightly faster expected revenue growth and improving profit margins, even as they temper future valuation multiples. Valuation Changes Discount Rate has risen slightly from 7.69% to 7.70%, reflecting a marginally higher required return.Narrative Update • Dec 12
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have trimmed their price target on Sensus Healthcare to approximately 8 dollars from about 10 dollars, citing softer expected revenue growth, lower projected profit margins, and a higher assumed future price to earnings multiple that together point to a more conservative valuation outlook. What's in the News Peer reviewed data from a single center retrospective study in Dermatologic Therapy show that Sensus Healthcare's superficial radiotherapy technology combined with punch excision significantly improved keloid outcomes over one year, including reductions in pain, itching, thickness and irregularity of scars, with no severe adverse reactions reported (study in Dermatologic Therapy).Analysis Article • Nov 19
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Rockets 26% But Many Are Still Ignoring The Company
The Sensus Healthcare, Inc. ( NASDAQ:SRTS ) share price has done very well over the last month, posting an excellent...Analysis Article • Oct 04
Insufficient Growth At Sensus Healthcare, Inc. (NASDAQ:SRTS) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) is a stock...Narrative Update • Sep 04
Increased CMS Reimbursement And International Expansion Will Unlock Demand
With no new analyst reasoning provided and both the discount rate and future P/E ratio remaining stable, the consensus fair value for Sensus Healthcare is unchanged at $8.00. What's in the News Sensus Healthcare's entire superficial radiation therapy (SRT) system portfolio received Medical Device Single Audit Program (MDSAP) certification.Analysis Article • Jul 12
Returns On Capital Are Showing Encouraging Signs At Sensus Healthcare (NASDAQ:SRTS)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...Analysis Article • May 06
Why Sensus Healthcare, Inc. (NASDAQ:SRTS) Could Be Worth Watching
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it received a lot of...Analysis Article • Mar 13
Investors Shouldn't Be Too Comfortable With Sensus Healthcare's (NASDAQ:SRTS) Earnings
Despite posting some strong earnings, the market for Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) stock hasn't moved much...Analysis Article • Feb 25
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares are down a considerable 27% in...Analysis Article • Feb 08
Revenue Beat: Sensus Healthcare, Inc. Beat Analyst Estimates By 5.6%
Shareholders in Sensus Healthcare, Inc. ( NASDAQ:SRTS ) had a terrible week, as shares crashed 29% to US$5.84 in the...New Narrative • Jan 07
SRTS Market Outlook
Sensus Healthcare (NASDAQ: SRTS) operates in the Healthcare sector and is part of the Medical Devices industry. Specifically, it focuses on the development and commercialization of non-invasive SuperfAnalysis Article • Dec 18
We Think Sensus Healthcare (NASDAQ:SRTS) Might Have The DNA Of A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Analysis Article • Nov 19
Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders of Sensus Healthcare, Inc. ( NASDAQ:SRTS ) will be pleased this week, given that the stock price is up 19...Analysis Article • Nov 12
Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares
It's not a stretch to say that Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) price-to-earnings (or "P/E") ratio of 17.4x...Analysis Article • Oct 03
At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it saw a significant share...
New Narrative • Sep 28
Fair Deal Agreement And Global Expansion Set To Revolutionize Revenue And Margins
Strategic shift towards recurring revenue with the Fair Deal Agreement model indicates potential for significant revenue growth from 2025.Analysis Article • May 12
Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Analysis Article • Apr 16
Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
With a price-to-sales (or "P/S") ratio of 2.1x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) may be sending bullish signals...Analysis Article • Feb 11
Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The investors in Sensus Healthcare, Inc. 's ( NASDAQ:SRTS ) will be rubbing their hands together with glee today, after...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Sensus Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 23 | -8 | 14 | 7 |
| 31 Dec 25 | 27 | -8 | 14 | 8 |
| 30 Sep 25 | 36 | -3 | 15 | 7 |
| 30 Jun 25 | 38 | -1 | 14 | 7 |
| 31 Mar 25 | 39 | 2 | 14 | 6 |
| 31 Dec 24 | 42 | 7 | 12 | 4 |
| 30 Sep 24 | 41 | 9 | 10 | 3 |
| 30 Jun 24 | 36 | 7 | 10 | 4 |
| 31 Mar 24 | 32 | 5 | 10 | 4 |
| 31 Dec 23 | 24 | 0 | 11 | 4 |
| 30 Sep 23 | 25 | -1 | 12 | 4 |
| 30 Jun 23 | 30 | 2 | 12 | 4 |
| 31 Mar 23 | 38 | 6 | 12 | 4 |
| 31 Dec 22 | 45 | 24 | 11 | 3 |
| 30 Sep 22 | 44 | 27 | 11 | 3 |
| 30 Jun 22 | 41 | 25 | 10 | 3 |
| 31 Mar 22 | 34 | 21 | 10 | 4 |
| 31 Dec 21 | 27 | 4 | 9 | 3 |
| 30 Sep 21 | 19 | 0 | 9 | 3 |
| 30 Jun 21 | 15 | -2 | 9 | 3 |
| 31 Mar 21 | 11 | -4 | 8 | 4 |
| 31 Dec 20 | 10 | -7 | 9 | 4 |
| 30 Sep 20 | 13 | -7 | 11 | 4 |
| 30 Jun 20 | 17 | -6 | 12 | 5 |
| 31 Mar 20 | 24 | -3 | 13 | 6 |
| 31 Dec 19 | 27 | -2 | 13 | 6 |
| 30 Sep 19 | 27 | -3 | 13 | 7 |
| 30 Jun 19 | 27 | -2 | 13 | 7 |
| 31 Mar 19 | 26 | -3 | 13 | 7 |
| 31 Dec 18 | 26 | -2 | 13 | 6 |
| 30 Sep 18 | 25 | -3 | 12 | 6 |
| 30 Jun 18 | 23 | -3 | 12 | 6 |
| 31 Mar 18 | 22 | -3 | 12 | 6 |
| 31 Dec 17 | 21 | -4 | 12 | 5 |
| 30 Sep 17 | 19 | -3 | 12 | 5 |
| 30 Jun 17 | 18 | -2 | 11 | 3 |
| 31 Mar 17 | 16 | -2 | 10 | 3 |
| 31 Dec 16 | 15 | 0 | 8 | 2 |
| 30 Sep 16 | 14 | 0 | 7 | 1 |
| 30 Jun 16 | 13 | 0 | 7 | 1 |
| 31 Mar 16 | 11 | 0 | 6 | 1 |
| 31 Dec 15 | 10 | -1 | 5 | 1 |
| 30 Sep 15 | 8 | -2 | 5 | 2 |
Quality Earnings: SRTS is currently unprofitable.
Growing Profit Margin: SRTS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SRTS is unprofitable, and losses have increased over the past 5 years at a rate of 31.4% per year.
Accelerating Growth: Unable to compare SRTS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SRTS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.8%).
Return on Equity
High ROE: SRTS has a negative Return on Equity (-17.07%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/28 18:19 |
| End of Day Share Price | 2026/07/28 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sensus Healthcare, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |